Genezen

Genezen is a specialized CDMO focused exclusively on viral vector manufacturing, a critical bottleneck in the cell and gene therapy (CGT) sector. The company leverages over a decade of experience and significant manufacturing capacity across two major US biotech hubs to serve therapy developers. Its business model is built on providing flexible, science-driven development and manufacturing services, positioning it as a key enabler for biotech companies advancing novel therapies to market. Recent strategic partnerships with therapy developers like Atsena Therapeutics and Humane Genomics underscore its growing role in the CGT ecosystem.

Specialized CDMO providing viral vector manufacturing services for Lentiviral, Retroviral, and Adeno-Associated Viral (AAV) vectors, including plasmid design, process development, analytical testing, and cGMP manufacturing.

Genezen competes in the viral vector CDMO space against large, diversified CDMOs (e.g., Lonza, Catalent) and other specialized players. Its differentiation lies in its focused expertise, flexible client partnership model, and dedicated, state-of-the-art facilities for multiple vector types.